R-3750 in Patients With Mild to Moderate Ulcerative Colitis
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to determine the safety and tolerability of orally taken probiotic
(R-3750) in patients with mild to moderate ulcerative colitis.
Patients will take an oral dosage of probiotic (R-3750) and provide patient-reported and
physician scored measures of their colitis. Blood and fecal evaluations of inflammation and
assessment of probiotic (R-3750) on fecal levels will also be measured.